{"transactions":[{"id":4629678,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-05T20:03:34.000Z","date":"2026-10-01","kind":"sale","planned":false,"acquired":false,"shares":11767,"price":2.8604,"value":33658.3268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 64,418 shares represent restricted stock units."}],"balance_after":155983,"source":{"system":"sec-edgar","filing":"0001501697-26-000078","document":"wk-form4_1791230611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000078/wk-form4_1791230611.xml","form_type":"4"}},{"id":720851,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:23:25.000Z","date":"2026-06-30","kind":"sale","planned":false,"acquired":false,"shares":8543,"price":4.2641,"value":36428.2063,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.21 to $4.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 96,627 shares represent restricted stock units."}],"balance_after":167750,"source":{"system":"sec-edgar","filing":"0001501697-26-000065","document":"wk-form4_1782937402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000150169726000065/wk-form4_1782937402.xml","form_type":"4"}},{"id":780547,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-13T20:02:44.000Z","date":"2026-05-12","kind":"sale","planned":false,"acquired":false,"shares":16961,"price":4.2934,"value":72820.3574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.20 to $4.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 128,836 shares represent restricted stock units."}],"balance_after":176293,"source":{"system":"sec-edgar","filing":"0001501697-26-000049","document":"wk-form4_1778702561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000150169726000049/wk-form4_1778702561.xml","form_type":"4"}},{"id":1010467,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-31T20:41:55.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":1552769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":1552769,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":1552769},"source":{"system":"sec-edgar","filing":"0001276750-25-000004","document":"wk-form4_1761943312.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000127675025000004/wk-form4_1761943312.xml","form_type":"4"}},{"id":1066227,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:14.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":352800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to\nthe Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based\nmilestones prior to February 12, 2026."}],"balance_after":352800,"derivative":{"exercise_price":3.14,"expiration_date":"2035-08-14","underlying":"Common Stock","underlying_shares":352800},"source":{"system":"sec-edgar","filing":"0001628280-25-040440","document":"wk-form4_1755217870.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000162828025040440/wk-form4_1755217870.xml","form_type":"4"}},{"id":1066226,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:14.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":1073249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to\nthe Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based\nmilestones prior to February 12, 2026."}],"balance_after":1073249,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":1073249},"source":{"system":"sec-edgar","filing":"0001628280-25-040440","document":"wk-form4_1755217870.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000162828025040440/wk-form4_1755217870.xml","form_type":"4"}},{"id":1066225,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-15T00:31:14.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":193254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive quarter thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders."}],"balance_after":193254,"source":{"system":"sec-edgar","filing":"0001628280-25-040440","document":"wk-form4_1755217870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000162828025040440/wk-form4_1755217870.xml","form_type":"4"}},{"id":1844638,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.55,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844637,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":280000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.49,"underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844636,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.3,"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844635,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":340000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":1,"underlying":"Common Stock","underlying_shares":340000},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844634,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":270216,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":0.9489,"underlying":"Common Stock","underlying_shares":270216},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844633,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.14,"underlying":"Common Stock","underlying_shares":83396},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844632,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":315000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.19,"underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844631,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.25,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1844630,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-26T16:05:21.000Z","date":"2023-06-26","kind":"other","planned":false,"acquired":false,"shares":17547,"price":9.1,"value":159677.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 420 shares of common stock of the Issuer (\"Company Common Stock\") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-016485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016485/doc4.xml","form_type":"4"}},{"id":1951019,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-16T17:52:37.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates."}],"balance_after":200000,"derivative":{"exercise_price":4.55,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-23-008752","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323008752/doc4.xml","form_type":"4"}},{"id":2073425,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T18:36:52.000Z","date":"2023-01-03","kind":"exercise","acquired":false,"shares":27021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":270216,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":27021},"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073424,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"exercise","acquired":false,"shares":1047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":297237,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":1047},"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073423,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"exercise","acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":298284,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073422,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":299084,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073421,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-29","kind":"exercise","acquired":false,"shares":13174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":311084,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":13174},"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073420,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":27021,"price":6.011,"value":162423.231,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":17127,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073419,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":27021,"price":0.9489,"value":25640.2269,"ownership":{"direct":true},"balance_after":44148,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073418,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":1047,"price":6.01,"value":6292.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":17127,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073417,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"exercise","acquired":true,"shares":1047,"price":0.9489,"value":993.4983,"ownership":{"direct":true},"balance_after":18174,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073416,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":800,"price":6.005,"value":4804.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":17127,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073415,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"exercise","acquired":true,"shares":800,"price":0.9489,"value":759.12,"ownership":{"direct":true},"balance_after":17927,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073414,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":12000,"price":6,"value":72000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":17127,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073413,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"exercise","acquired":true,"shares":12000,"price":0.9489,"value":11386.8,"ownership":{"direct":true},"balance_after":29127,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073412,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":214,"price":5.1085,"value":1093.219,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":17127,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073411,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-29","kind":"sale","acquired":false,"shares":13174,"price":6,"value":79044.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2073410,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2023-01-03T18:36:52.000Z","date":"2022-12-29","kind":"exercise","acquired":true,"shares":13174,"price":0.9489,"value":12500.8086,"ownership":{"direct":true},"balance_after":30087,"source":{"system":"sec-edgar","filing":"0000891293-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000001/primary_doc.xml","form_type":"4"}},{"id":2141617,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"exercise","acquired":false,"shares":609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":324258,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":609},"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141616,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":324867,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141615,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"exercise","acquired":false,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":324967,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141614,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":609,"price":6.27,"value":3818.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141613,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"exercise","acquired":true,"shares":609,"price":0.9489,"value":577.8801,"ownership":{"direct":true},"balance_after":17522,"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141612,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":100,"price":6.26,"value":626.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141611,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"exercise","acquired":true,"shares":100,"price":0.9489,"value":94.89,"ownership":{"direct":true},"balance_after":17013,"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141610,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":1400,"price":6.25,"value":8750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2141609,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-06T16:20:45.000Z","date":"2022-10-04","kind":"exercise","acquired":true,"shares":1400,"price":0.9489,"value":1328.46,"ownership":{"direct":true},"balance_after":18313,"source":{"system":"sec-edgar","filing":"0000891293-22-000047","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000047/primary_doc.xml","form_type":"4"}},{"id":2148051,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-03T18:26:58.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":326367,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148050,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":139841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":326667,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":139841},"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148049,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-29","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":466508,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148048,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-29","kind":"exercise","acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":466608,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148047,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":300,"price":6.25,"value":1875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148046,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":300,"price":0.9489,"value":284.67,"ownership":{"direct":true},"balance_after":17213,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148045,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":139841,"price":6.0465,"value":845548.6065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148044,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":139841,"price":0.9489,"value":132695.1249,"ownership":{"direct":true},"balance_after":156754,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148043,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":100,"price":6.01,"value":601.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148042,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-29","kind":"exercise","acquired":true,"shares":100,"price":0.9489,"value":94.89,"ownership":{"direct":true},"balance_after":17013,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148041,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":800,"price":6,"value":4800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2148040,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-10-03T18:26:58.000Z","date":"2022-09-29","kind":"exercise","acquired":true,"shares":800,"price":0.9489,"value":759.12,"ownership":{"direct":true},"balance_after":17713,"source":{"system":"sec-edgar","filing":"0000891293-22-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000046/primary_doc.xml","form_type":"4"}},{"id":2154428,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-09-20T16:59:57.000Z","date":"2022-09-16","kind":"exercise","acquired":false,"shares":22592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":467408,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":22592},"source":{"system":"sec-edgar","filing":"0000891293-22-000045","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000045/primary_doc.xml","form_type":"4"}},{"id":2154427,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-09-20T16:59:57.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":22592,"price":6.02,"value":136003.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000045","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000045/primary_doc.xml","form_type":"4"}},{"id":2154426,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-09-20T16:59:57.000Z","date":"2022-09-16","kind":"exercise","acquired":true,"shares":22592,"price":0.9489,"value":21437.5488,"ownership":{"direct":true},"balance_after":39505,"source":{"system":"sec-edgar","filing":"0000891293-22-000045","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000045/primary_doc.xml","form_type":"4"}},{"id":2154425,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-09-20T16:59:57.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":9516,"price":2.1165,"value":20140.614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000891293-22-000045","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000045/primary_doc.xml","form_type":"4"}},{"id":2228852,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-17T16:57:44.000Z","date":"2022-06-17","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One sixth of the shares underlying the option vested on 9/10/2021 and semi-annually thereafter until all the underlying shares will be fully vested on 3/10/2024."}],"balance_after":150000,"derivative":{"exercise_price":3.3,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000891293-22-000033","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000033/primary_doc.xml","form_type":"4"}},{"id":2228851,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-17T16:57:44.000Z","date":"2022-06-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One sixth of the shares underlying the option vested on 9/11/2020 and semi-annually thereafter until all the underlying shares will be fully vested on 3/11/2023."}],"balance_after":340000,"derivative":{"exercise_price":1,"expiration_date":"2030-03-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000891293-22-000033","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000033/primary_doc.xml","form_type":"4"}},{"id":2228850,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-06-17T16:57:44.000Z","date":"2022-06-17","kind":"sale","acquired":false,"shares":50000,"price":6.2501,"value":312505.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":7397,"source":{"system":"sec-edgar","filing":"0000891293-22-000033","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000033/primary_doc.xml","form_type":"4"}},{"id":2228849,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-06-17T16:57:44.000Z","date":"2022-06-17","kind":"exercise","acquired":true,"shares":50000,"price":3.3,"value":165000.0,"ownership":{"direct":true},"balance_after":57397,"source":{"system":"sec-edgar","filing":"0000891293-22-000033","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000033/primary_doc.xml","form_type":"4"}},{"id":2228848,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-06-17T16:57:44.000Z","date":"2022-06-17","kind":"sale","acquired":false,"shares":10000,"price":6,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":7397,"source":{"system":"sec-edgar","filing":"0000891293-22-000033","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000033/primary_doc.xml","form_type":"4"}},{"id":2228847,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-06-17T16:57:44.000Z","date":"2022-06-17","kind":"exercise","acquired":true,"shares":10000,"price":1,"value":10000.0,"ownership":{"direct":true},"balance_after":17397,"source":{"system":"sec-edgar","filing":"0000891293-22-000033","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000033/primary_doc.xml","form_type":"4"}},{"id":2230652,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-16T16:19:11.000Z","date":"2022-06-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":490000,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000891293-22-000032","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000032/primary_doc.xml","form_type":"4"}},{"id":2230651,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-06-16T16:19:11.000Z","date":"2022-06-14","kind":"sale","acquired":false,"shares":10000,"price":5.5,"value":55000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":7397,"source":{"system":"sec-edgar","filing":"0000891293-22-000032","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000032/primary_doc.xml","form_type":"4"}},{"id":2230650,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"common stock","published_at":"2022-06-16T16:19:11.000Z","date":"2022-06-14","kind":"exercise","acquired":true,"shares":10000,"price":0.9489,"value":9489.0,"ownership":{"direct":true},"balance_after":17397,"source":{"system":"sec-edgar","filing":"0000891293-22-000032","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000032/primary_doc.xml","form_type":"4"}},{"id":2338458,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T19:41:18.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates."}],"balance_after":280000,"derivative":{"exercise_price":4.49,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000899243-22-010771","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322010771/doc4.xml","form_type":"4"}},{"id":2338457,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-11T19:41:18.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1817,"price":2.108,"value":3830.236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":7397,"source":{"system":"sec-edgar","filing":"0000899243-22-010771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322010771/doc4.xml","form_type":"4"}},{"id":2338456,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-11T19:41:18.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":1782,"price":2.125,"value":3786.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":5580,"source":{"system":"sec-edgar","filing":"0000899243-22-010771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322010771/doc4.xml","form_type":"4"}},{"id":2793073,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-12T18:41:38.000Z","date":"2021-03-10","kind":"sale","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the Company's 2017 Equity Incentive Plan, which approval must occur within one year from the grant date."}],"balance_after":200000,"derivative":{"exercise_price":3.3,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-21-011363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924321011363/doc4.xml","form_type":"4"}},{"id":2793072,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-12T18:41:38.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":3798,"price":0.98,"value":3722.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":3798,"source":{"system":"sec-edgar","filing":"0000899243-21-011363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924321011363/doc4.xml","form_type":"4"}},{"id":3212038,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-qualified Stock Option","published_at":"2020-03-13T19:51:45.000Z","date":"2020-03-11","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the 2017 Equity Incentive Plan of the Company, which approval must occur within one year from the grant date."}],"balance_after":350000,"derivative":{"exercise_price":1,"expiration_date":"2030-03-11","underlying":"Common stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000891293-20-000018","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129320000018/primary_doc.xml","form_type":"4"}},{"id":3643184,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-02-21T18:46:02.000Z","date":"2019-02-19","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the Option shall vest on the one year anniversary of February 19, 2019, and 1/3 of the shares shall vest annually thereafter on February 19, subject to Reporting Person continuing to be an employee or service provider on each date, such that the Option shall be fully vested on February 19, 2022."}],"balance_after":500000,"derivative":{"exercise_price":0.9489,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000891293-19-000010","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129319000010/primary_doc.xml","form_type":"4"}},{"id":3811066,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-09-20T17:03:44.000Z","date":"2018-09-18","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will fully vest upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019."}],"balance_after":125000,"derivative":{"exercise_price":1.88,"expiration_date":"2028-09-18","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000891293-18-000087","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129318000087/primary_doc.xml","form_type":"4"}},{"id":3929281,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-05-17T16:49:19.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":83396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in six equal semi-annual installments over a three-year period commencing on March 9, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on March 9, 2021."}],"balance_after":83396,"derivative":{"exercise_price":4.14,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":83396},"source":{"system":"sec-edgar","filing":"0000891293-18-000058","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129318000058/primary_doc.xml","form_type":"4"}},{"id":4183274,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-19T16:11:48.000Z","date":"2017-08-31","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 3, 2017, the reporting person filed a Form 4 which inadvertently reported that, on August 1, 2017 (the first day of the reporting person's employment with CTIC), CTIC granted the reporting person an option to purchase 25,000 shares of CTIC Common Stock.  In fact, as reported in this amendment, such stock option was not granted until August 31, 2017 (the last day of the month in which the reporting person was first employed by CTIC)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options will vest over a period of one year from the grant date in twelve equal monthly installments.  The grant will accelerate and fully vest should Mr. Kirske's employment be terminated by the Company without cause within the first six months after the grant date."}],"balance_after":25000,"derivative":{"exercise_price":3.25,"expiration_date":"2027-08-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000891293-17-000109","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129317000109/primary_doc.xml","form_type":"4/A","original_submission_date":"2017-08-03"}},{"id":4196136,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-03T16:12:16.000Z","date":"2017-09-29","kind":"grant","acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest in six equal semi-annual installments over a three-year period beginning September 29, 2017 subject to continued employment by CTIC through the applicable vesting dates."}],"balance_after":315000,"derivative":{"exercise_price":3.19,"expiration_date":"2027-09-29","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0000891293-17-000106","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129317000106/primary_doc.xml","form_type":"4"}},{"id":4244508,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-08-03T19:02:32.000Z","date":"2017-08-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest over a period of one year from the grant date in twelve equal monthly installments. The grant will accelerate and fully vest should Mr. Kirske's employment be terminated by the Company without cause within the first six months after the grant date."}],"balance_after":25000,"derivative":{"exercise_price":3.43,"expiration_date":"2027-08-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-17-019737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924317019737/doc4.xml","form_type":"4"}}]}